Estadístiques de Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
Visites totals
views | |
---|---|
Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date | 201 |
Visites totals per mes
views | |
---|---|
October 2024 | 0 |
November 2024 | 1 |
December 2024 | 0 |
January 2025 | 0 |
February 2025 | 0 |
March 2025 | 0 |
April 2025 | 0 |
Visites al fitxer
views | |
---|---|
remon-cmr-nivo.pdf(legacy) | 201 |
remon-cmr-nivo.pdf | 31 |
Vistes principals per país
views | |
---|---|
United States | 134 |
United Kingdom | 9 |
Australia | 8 |
Germany | 6 |
Spain | 5 |
Brazil | 4 |
Japan | 4 |
China | 3 |
Egypt | 3 |
Greece | 3 |
South Korea | 3 |
Sweden | 3 |
Canada | 2 |
Czechia | 2 |
Hong Kong SAR China | 2 |
France | 1 |
India | 1 |
Italy | 1 |
Malaysia | 1 |
Serbia | 1 |
Slovakia | 1 |
Visites principals per ciutat
views | |
---|---|
Ashburn | 18 |
Fairfield | 17 |
San Ramon | 14 |
Redwood City | 12 |
Mountain View | 6 |
Menlo Park | 5 |
Cambridge | 4 |
Carapicuíba | 4 |
Ridge | 4 |
Tustin | 4 |
Berkeley | 3 |
Boardman | 3 |
Leeds | 3 |
Princeton | 3 |
Seoul | 3 |
Shenzhen | 3 |
Tokyo | 3 |
Bedworth | 2 |
Cairo | 2 |
Hong Kong | 2 |
London | 2 |
Los Angeles | 2 |
Marblehead | 2 |
Murcia | 2 |
Sacramento | 2 |
San Diego | 2 |
Seattle | 2 |
Sydney | 2 |
Tallahassee | 2 |
Thessaloníki | 2 |
Albuquerque | 1 |
Altamonte Springs | 1 |
Ann Arbor | 1 |
Arganda | 1 |
Barcelona | 1 |
Bethesda | 1 |
Brisbane | 1 |
Brooklyn | 1 |
Charleston | 1 |
Columbus | 1 |
Kyoto | 1 |
Maryborough | 1 |
Middletown | 1 |
Naples | 1 |
Northolt | 1 |
Patras | 1 |
Petaling Jaya | 1 |
Philadelphia | 1 |
Pinjarra | 1 |
Portland | 1 |
Scarborough | 1 |
Stockholm | 1 |
Subotica | 1 |
Tempe | 1 |
Thane | 1 |
Toronto | 1 |
Valladolid | 1 |
Wichita | 1 |
Yellowknife | 1 |